Verification register Bio, Health & Neuro
Current reading
Readiness band and full integer triple
AI-assisted assembly · derived results
Readiness band
Ready
Primary summary from verified readiness
- Confidence
- 74% · fresh
- Computed at
- 2026-07-23T12:36:47.753378+00:00
- Claimed
- 72
- Reported
- 72
- Verified
- 72
- Gap
- 0
Public ambition and stated capability
Observed practitioner reporting
Independently supported evidence
Claimed and verified align
Evidence strength Critical
Decision
What the current evidence supports
Human editorial judgment · 2026-07-23
Track; not yet
- Why
- Phase 3 SHASTA-3/SHASTA-4 topline results are strong (79-81% triglyceride reduction, up to 100% pancreatitis-event reduction in the highest-risk subgroup) and build on an already-commercialized global franchise (REDEMPLO approved in US/EU/China/Australia/Canada for FCS), but the broader severe-hypertriglyceridemia indication itself is not yet filed with the FDA and the full peer-reviewed dataset is still pending.
- Next
- Revisit after the 2026-08-30 ESC Congress full 12-month data readout and confirm FDA sNDA filing/acceptance for the broader severe-hypertriglyceridemia indication before year-end 2026.
Constraints
Blockers
No named blocker is present in the current public projection.
Evidence summary
Derived counts
AI-assisted assembly
- Total
- 6
- Tier 1
- 0
- Tier 2
- 3
- Tier 3
- 3
- Supports
- 4
- Contradicts
- 0
- Context
- 2
- Latest observed
- 2026-07-22
Counts and dates only. Raw signals, private excerpts, trust records, and internal corpus material are not published here.
Publication record
Revisions
Initial public reading
- 2026-07-23 Reading moved from ready to ready.